Abacavir

Chemical formula: C₁₄H₁₈N₆O Molecular mass: 286.332 g/mol PubChem compound: 441300

Therapeutic indications

Abacavir is indicated for:

Human immunodeficiency virus infection

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Abacavir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children.

The demonstration of the benefit of abacavir is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy.

Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

600 mg daily

For patients weighing ≥25 kg 600 mg daily, for patients weighing ≥20 kg to <25 kg 450 mg daily and for patients weighing 14 to <20 kg 300 mg daily

Contraindications

Abacavir is contraindicated in the following cases:

Positive HLA-B*5701 status

HLA-B*57:01 positive

End-stage renal disease

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.